TAVLESSE is the 1st AND ONLY TARGETED AGENT that helps prevent immune-mediated platelet destruction1-3 - NOW AVAILABLE IN THE UK
TAVLESSE (fostamatinib disodium hexahydrate) is a spleen tyrosine kinase (SYK) inhibitor indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
Who is TAVLESSE for? TAVLESSE is for adult patients with chronic ITP who have had an insufficient response to previous treatments
How is it administered? TAVLESSE is an oral tablet taken twice daily with or without food
How does it work in the body? TAVLESSE is a tyrosine kinase inhibitor that targets the spleen tyrosine kinase (SYK).1 The major active metabolite of TAVLESSE, R406, reduces the antibody-mediated destruction of platelets.
TAVLESSE differs from other treatments for chronic ITP by reducing SYK mediated platelet destruction,2 not stimulating increased platelet production4,5
When will more information be available? We will continue to update this landing page as more information about Tavlesse becomes available.
THE TAVLESSE DIFFERENCE: A unique mode of action targeted to limit platelet destruction Fostamatinib inhibits SYK.1-3
Tavlesse (via its active metabolite) reduces antibody-mediated platelet destruction2
SYK = spleen tyrosine kinase; ITP = immune thrombocytopenia; PI3K = phosphatidylinositol-3-kinase; SLP76 = SH2-domain-containing leukocyte protein of 76 kDa; Rac = Rac family small GTPase
* R406 is the active matabolite of Tavlesse®. 1. Bussel JB, et al. Am J Hematol. 2018; 93:921-930. Doi: 10.1002/ajh.25125. 2. Tavlesse Summary of product characteristics. Grifols April, 2020. 3. Newland A, et al. Immunotherapy. 2018:10(1):9-25. 4. Nplate (romiplostim) Summary of product characteristics. Available at https:// www.medicines.org.uk/emc/product/567/smpc (last accessed August 2020) 5. Revolade (eltrombopag) Summary of product characteristics. Available at https://www.medicines.org.uk/emc/product/508/smpc (last accessed August 2020) 6. Shih A, et al. Press Med. 2014;43:e87-e95. 7. Nimmerjahn F, et al. Nature. 2008;8:34-47.